MDRNA, Inc. Appoints James M. Karis to Its Board of Directors
BOTHELL, WA--(Marketwire - August 11, 2009) - MDRNA, Inc. (NASDAQ: MRNA) announced today that
James M. Karis has been appointed to the Company's Board of Directors. His
appointment brings the number of MDRNA board members to six.
"I am pleased to welcome James Karis to MDRNA's Board of Directors," stated
Bruce R. Thaw, Chairman of the Board of Directors. "James has spent 30
years in the pharmaceutical, healthcare services and medical device
industries and brings extensive corporate strategy and operations
experience to MDRNA, and a track record that encompasses both corporate
turnarounds and building successful businesses through organic growth,
acquisitions and financing."
Previously, Mr. Karis served as President, Chief Executive Officer and a
Director of Entelos from January 2000 until May 2009. Prior to Entelos, he
held senior positions in the contract research industry, serving as Chief
Operating Officer and President of PAREXEL International Corporation, and
earlier, as Chief Operating Officer of Pharmaco International. He was the
Vice President of International Operations for Baxter International and a
founder of KMR Group, a leading pharmaceutical R&D benchmarking consulting
firm. Mr. Karis serves on the Board of BayBio, an advocacy group for
Northern California's life science community. He has a B.S. in management
and economics from Purdue University and a Masters in applied economics
from The American University.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and
commercialization of therapeutic products based on RNA interference (RNAi).
Our goal is to improve human health through the development of RNAi-based
compounds and drug delivery technologies that together provide superior
therapeutic options for patients. Over the past decade, we have developed
substantial capabilities in molecular biology, cellular biology, lipid
chemistry, peptide chemistry, pharmacology and bioinformatics, which we are
applying to a wide range of RNAi technologies and delivery approaches.
These capabilities plus the in-licensing of key RNAi-related intellectual
property have rapidly enabled us to become a leading RNAi-based
therapeutics company with a pre-clinical pipeline in key therapeutic areas
including oncology, metabolic disorders and inflammation. Through our
capabilities, expertise and know-how, we are incorporating multiple RNAi
technologies as well as peptide- and lipid-based delivery approaches into a
single integrated drug discovery platform that will be the engine for our
clinical pipeline as well as a versatile platform for establishing broad
therapeutic partnerships with biotechnology and pharmaceutical companies.
We are also investing in new technologies that we expect to lead to safer
and more effective RNAi-based therapeutics while aggressively building upon
our broad and extensive intellectual property estate. By combining broad
expertise in siRNA science with proven delivery platforms and a strong IP
position, MDRNA is well positioned as a leading RNAi-based drug discovery
and development company. Additional information about MDRNA, Inc. is
available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statements
Statements made in this news release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results
to differ materially from those projected or suggested. Factors that could
cause actual results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of MDRNA or a
subsidiary to obtain additional funding; (ii) the ability of MDRNA or a
subsidiary to attract and/or maintain manufacturing, research, development
and commercialization partners; (iii) the ability of MDRNA, a subsidiary
and/or a partner to successfully complete product research and development,
including preclinical and clinical studies and commercialization; (iv) the
ability of MDRNA, a subsidiary and/or a partner to obtain required
governmental approvals; and (v) the ability of MDRNA, a subsidiary and/or a
partner to develop and commercialize products that can compete favorably
with those of competitors. Additional factors that could cause actual
results to differ materially from those projected or suggested in any
forward-looking statements are contained in MDRNA's most recent periodic
reports on Form 10-K and Form 10-Q that are filed with the Securities and
Exchange Commission. MDRNA assumes no obligation to update and supplement
forward-looking statements because of subsequent events.
Contact Information: Contact:
Matthew D. Haines
Senior Director, Investor Relations and Corporate Communications
(312) 944-6784 x 316 or